BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, Inoue Y, Kusunoki M. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol. 2012;19 Suppl 3:S518-S527. [PMID: 21845497 DOI: 10.1245/s10434-011-1993-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Shantha Kumara HMC, Pettke E, Shah A, Yan X, Cekic V, Downing MA, Gandhi ND, Whelan RL. Plasma levels of the proangiogenic protein CXCL16 remains elevated for 1 month after minimally invasive colorectal cancer resection. World J Surg Oncol 2018;16:132. [PMID: 29981574 DOI: 10.1186/s12957-018-1418-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Yang X, Wei Y, Sheng F, Xu Y, Liu J, Gao L, Yang J, Sun X, Huang J, Guo Q. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer. Aging (Albany NY) 2021;13:17548-67. [PMID: 34233297 DOI: 10.18632/aging.203245] [Reference Citation Analysis]
3 Heras SCDL, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol 2018; 24(42): 4738-4749 [PMID: 30479461 DOI: 10.3748/wjg.v24.i42.4738] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
4 Yu X, Guo C, Fisher PB, Subjeck JR, Wang XY. Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology. Adv Cancer Res 2015;128:309-64. [PMID: 26216637 DOI: 10.1016/bs.acr.2015.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
5 Hattermann K, Held-Feindt J, Ludwig A, Mentlein R. The CXCL16-CXCR6 chemokine axis in glial tumors. J Neuroimmunol 2013;260:47-54. [PMID: 23628207 DOI: 10.1016/j.jneuroim.2013.04.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
6 Montalbán-Hernández K, Cantero-Cid R, Lozano-Rodríguez R, Pascual-Iglesias A, Avendaño-Ortiz J, Casalvilla-Dueñas JC, Bonel Pérez GC, Guevara J, Marcano C, Barragán C, Valentín J, Del Fresno C, Aguirre LA, López Collazo E. Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients. Cancers (Basel) 2021;13:3896. [PMID: 34359797 DOI: 10.3390/cancers13153896] [Reference Citation Analysis]
7 Lim SH, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014;67:848-853. [PMID: 25008452 DOI: 10.1136/jclinpath-2014-202499] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
8 Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol 2015;27:445-51. [PMID: 26447875 DOI: 10.1097/CCO.0000000000000225] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
9 AbdelMageed M, Ali H, Olsson L, Lindmark G, Hammarström ML, Hammarström S, Sitohy B. The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome. Int J Mol Sci 2019;20:E5793. [PMID: 31752131 DOI: 10.3390/ijms20225793] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 139] [Cited by in F6Publishing: 137] [Article Influence: 19.9] [Reference Citation Analysis]
11 Veinotte L, Gebremeskel S, Johnston B. CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control. Oncoimmunology 2016;5:e1160979. [PMID: 27471636 DOI: 10.1080/2162402X.2016.1160979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
12 Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. World J Gastroenterol 2019; 25(31): 4383-4404 [PMID: 31496619 DOI: 10.3748/wjg.v25.i31.4383] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
13 Xu JM, Weng MZ, Song FB, Chen JY, Zhang JY, Wu JY, Qin J, Jin T, Wang XL. Blockade of the CXCR6 signaling inhibits growth and invasion of hepatocellular carcinoma cells through inhibition of the VEGF expression. Int J Immunopathol Pharmacol 2014;27:553-61. [PMID: 25572735 DOI: 10.1177/039463201402700411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lang K, Bonberg N, Robens S, Behrens T, Hovanec J, Deix T, Braun K, Roghmann F, Noldus J, Harth V, Jöckel KH, Erbel R, Tam YC, Tannapfel A, Käfferlein HU, Brüning T. Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas. Oncotarget 2017;8:104946-59. [PMID: 29285224 DOI: 10.18632/oncotarget.20737] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Xing YN, Zhang JY, Xu HM. The roles of serum CXCL16 in circulating Tregs and gastrointestinal stromal tumor cells. Onco Targets Ther 2016;9:3939-49. [PMID: 27418838 DOI: 10.2147/OTT.S105245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kulasingam V, Prassas I, Diamandis EP. Towards personalized tumor markers. NPJ Precis Oncol 2017;1:17. [PMID: 29872704 DOI: 10.1038/s41698-017-0021-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
17 Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. World J Gastroenterol 2017; 23(34): 6212-6219 [PMID: 28974887 DOI: 10.3748/wjg.v23.i34.6212] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
18 Fang Y, Henderson FC Jr, Yi Q, Lei Q, Li Y, Chen N. Chemokine CXCL16 expression suppresses migration and invasiveness and induces apoptosis in breast cancer cells. Mediators Inflamm 2014;2014:478641. [PMID: 24864132 DOI: 10.1155/2014/478641] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
19 Zhou J, Xiang Y, Yoshimura T, Chen K, Gong W, Huang J, Zhou Y, Yao X, Bian X, Wang JM. The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int 2014;2014:751392. [PMID: 25110692 DOI: 10.1155/2014/751392] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
20 Di Caro G, Marchesi F, Galdiero MR, Grizzi F. Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. Expert Rev Mol Diagn 2014;14:387-99. [PMID: 24649823 DOI: 10.1586/14737159.2014.900443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
21 Na KY, Kim HS, Jung WW, Sung JY, Kalil RK, Kim YW, Park YK. CXCL16 and CXCR6 in Ewing sarcoma family tumor. Hum Pathol 2014;45:753-60. [PMID: 24507753 DOI: 10.1016/j.humpath.2013.09.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gooden MJ, Wiersma VR, Boerma A, Leffers N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AM, Daemen T, Nijman HW, Bremer E. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. Br J Cancer 2014;110:1535-44. [PMID: 24518602 DOI: 10.1038/bjc.2014.55] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
23 Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res 2015;21:2840-50. [PMID: 25712684 DOI: 10.1158/1078-0432.CCR-14-2777] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
24 Wehr A, Tacke F. The Roles of CXCL16 and CXCR6 in Liver Inflammation and Fibrosis. Curr Pathobiol Rep 2015;3:283-90. [DOI: 10.1007/s40139-015-0090-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
25 Korbecki J, Bajdak-Rusinek K, Kupnicka P, Kapczuk P, Simińska D, Chlubek D, Baranowska-Bosiacka I. The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases. Int J Mol Sci 2021;22:3490. [PMID: 33800554 DOI: 10.3390/ijms22073490] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 2013;4:1795. [PMID: 23653207 DOI: 10.1038/ncomms2766] [Cited by in Crossref: 221] [Cited by in F6Publishing: 224] [Article Influence: 27.6] [Reference Citation Analysis]
27 Hou KZ, Fu ZQ, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol 2015; 21(2): 475-483 [PMID: 25593462 DOI: 10.3748/wjg.v21.i2.475] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
28 Pączek S, Łukaszewicz-Zając M, Mroczko B. Chemokines-What Is Their Role in Colorectal Cancer? Cancer Control 2020;27:1073274820903384. [PMID: 32103675 DOI: 10.1177/1073274820903384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Gowhari Shabgah A, Qasim MT, Mojtaba Mostafavi S, Olegovna Zekiy A, Ezzatifar F, Ahmadi M, Mohammadian Haftcheshmeh S, Gholizadeh Navashenaq J. CXC chemokine ligand 16: a Swiss army knife chemokine in cancer. Expert Rev Mol Med 2021;23:e4. [PMID: 33880989 DOI: 10.1017/erm.2021.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer 2015;15:441. [PMID: 26021984 DOI: 10.1186/s12885-015-1446-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
31 Łukaszewicz-Zając M, Mroczko B. Circulating Biomarkers of Colorectal Cancer (CRC)-Their Utility in Diagnosis and Prognosis. J Clin Med 2021;10:2391. [PMID: 34071492 DOI: 10.3390/jcm10112391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Vansaun MN, Mendonsa AM, Lee Gorden D. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One. 2013;8:e73054. [PMID: 24039859 DOI: 10.1371/journal.pone.0073054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
33 Li Y, Fu LX, Zhu WL, Shi H, Chen LJ, Ye B. Blockade of CXCR6 reduces invasive potential of gastric cancer cells through inhibition of AKT signaling. Int J Immunopathol Pharmacol 2015;28:194-200. [PMID: 25921630 DOI: 10.1177/0394632015584502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
34 Liu Y, Wang J, Ni T, Wang L, Wang Y, Sun X. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget 2016;7:25328-39. [PMID: 27015366 DOI: 10.18632/oncotarget.8291] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
35 Moelants EA, Mortier A, Van Damme J, Proost P. In vivo regulation of chemokine activity by post-translational modification. Immunol Cell Biol 2013;91:402-7. [PMID: 23628804 DOI: 10.1038/icb.2013.16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
36 Han J, Fu R, Chen C, Cheng X, Guo T, Huangfu L, Li X, Du H, Xing X, Ji J. CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways. Int J Biol Sci 2021;17:2841-52. [PMID: 34345211 DOI: 10.7150/ijbs.57826] [Reference Citation Analysis]